Specify a stock or a cryptocurrency in the search bar to get a summary
Hikma Pharmaceuticals PLC
H5PHikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom. Address: 1 New Burlington Place, London, United Kingdom, W1S 2HR
Analytics
WallStreet Target Price
1 760.71 GBXP/E ratio
29.4615Dividend Yield
3.19 %Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures H5P
Dividend Analytics H5P
Dividend growth over 5 years
77 %Continuous growth
8 yearsPayout Ratio 5 years average
54 %Dividend History H5P
Stock Valuation H5P
Financials H5P
Results | 2019 | Dynamics |